ERBB2 and breast cancer: In a phase Ib trial, trastuzumab-deruxtecan was effective in HER2-low advanced BC [24] and the FDA recently granted breakthrough therapy designation to trastuzumab deruxtecan for the treatment of HER2-low metastatic BC based on the Destiny-Breast04 trial results [25].